Inclusion Criteria:  Written informed consent. Aged between 14 and 65, both genders Positive suggestive clinical history of intermittent or persistent moderate to severe rhinitis /rhinoconjunctivitis, with or without moderate intermittent or persistent asthma,according to GEMA 5.0, due to grass and cupressaceae pollen. Subjects with a positive skin prick-test (wheal sixe >5 mm diameter). The positive and negative control of the test should give consistent results and whose determination does not exceed 1 year prior to the baseline visit. Specific immunoglobulin E ≥ class 3 , against grass and cupressaceae pollen (InmunoCAP® o Immulite) and whose determination does not exceed 1 year prior to the inclusion visit. Women of childbearing age (from menarche) must present a urine pregnancy test with a negative result at the time of joining the trial. Women of childbearing potential, and men participating in the trial, should commit to using an appropriate method of contraception. Medically acceptable methods of contraception are intrauterine devices placed at least 3 months in advance, surgical sterilization (for example, tubal ligation), barrier methods, or the use of oral contraceptives. Subjects with asthma must be diagnosed according to the GEMA 5.0 guideline. Subjects capable of complying with the dosing regimen. Subjects who own a smartphone for symptom registration and medication  Exclusion Criteria:  Subjects polisensitised to other aeroallergens but sensitisation to epithelia with exposure and occasional symptoms or sensitisation to pollen noncoseasonal with cupressus or grasses. Subjects who have received prior immunotherapy in the preceding 5 years for any of the allergens tested or a cross-reactive allergen or are currently receiving immunotherapy with any allergen. Subjects in which immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee. Subjects have not granted written informed consent. Subjects with severe or uncontrolled intermittent or persistent asthma, with an FEV1 <70% with respect to the reference value despite adequate pharmacological treatment at the time of inclusion in the trial. Likewise, subjects with intermittent or persistent rhinitis / rhinoconjunctivitis with severe symptoms in which the suspension of oral or systemic antihistamine treatment is contraindicated. Subjects who have previously had a severe secondary reaction during the prick test diagnostic skin test. Subjects treated with beta-blockers. Clinically unstable subjects at the time of inclusion in the trial (acute asthmatic exacerbation, respiratory infection, febrile process, acute urticaria, etc.). Subjects with active chronic urticaria, severe dermographism, severe atopic dermatitis, sunburn, active psoriasis with lesions in areas where skin tests will be performed, or a history of hereditary angioedema. Subjects who have any pathology in which adrenaline administration is contraindicated (hyperthyroidism, HTN, heart disease, etc.). Subjects with any other disease not related to moderate rhinoconjunctivitis or asthma, but potentially serious and that may interfere with treatment and follow-up (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multioperated patients, kidney disease,). Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies. Subject whose condition prevents from offering cooperation and/ or who has severe psychiatric disorders. Subjects with a known allergy to components of the investigational medicinal product other than the allergen. Subjects with lower respiratory diseases other than asthma such as emphysema or bronchiectasis. Subjects who are direct relatives of the researchers. Pregnant or lactating women.